Interestingly, acitretin alone treated CML CD34+ cells showed a significant reduction in cell viability compared to imatinib alone, 9cRA alone, or Bexa alone or in combination (Figure 3A). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.